|
|
Blood, 1 March 2007, Vol. 109, No. 5, pp. 2058-2065.
Prepublished online as a Blood First Edition Paper on November 16, 2006; DOI 10.1182/blood-2006-04-016451.
 Previous Article | Table of Contents | Next Article 
IMMUNOBIOLOGY
Galectin-1: a key effector of regulation mediated by CD4+CD25+ T cells
Marina I. Garín1,5,
Chung-Ching Chu1,
Dela Golshayan1,2,
Eva Cernuda-Morollón3,
Robin Wait4, and
Robert I. Lechler1
1 Immunoregulation Laboratory, Department of Nephrology and Transplantation, King's College London School of Medicine at Guy's, King's College and St Thomas' Hospitals, London, United Kingdom;
2 Division of Nephrology and Transplant Centre, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland;
3 Ludwig Institute for Cancer Research, Royal Free and University College School of Medicine, London, United Kingdom;
4 Kennedy Institute of Rheumatology, Arthritis Research Campaign Building, Faculty of Medicine, Imperial College London, United Kingdom;
5 Laboratorio de Hematopoyesis y Terapia Génica, Centro de Investigaciones Energéticas Medioambientales y Tecnológicas (CIEMAT), Madrid, Spain
The naturally occurring population of dedicated regulatory T cells that coexpress CD4 and CD25 is known to play a key role in the maintenance of peripheral T-cell tolerance; however, their mechanism of action has remained obscure. Here we report that a member of the family of ß-galactoside–binding proteins, galectin-1, is overexpressed in regulatory T cells, and that expression is increased after activation. Most importantly, blockade of galectin-1 binding significantly reduced the inhibitory effects of human and mouse CD4+CD25+ T cells. Reduced regulatory activity was observed in CD4+CD25+ T cells obtained from galectin-1–homozygous null mutant mice. These results suggest that galectin-1 is a key effector of the regulation mediated by these cells.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
S. Bi, L. A. Earl, L. Jacobs, and L. G. Baum
Structural Features of Galectin-9 and Galectin-1 That Determine Distinct T Cell Death Pathways
J. Biol. Chem.,
May 2, 2008;
283(18):
12248 - 12258.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. Pacienza, R. G. Pozner, G. A. Bianco, L. P. D'Atri, D. O. Croci, S. Negrotto, E. Malaver, R. M. Gomez, G. A. Rabinovich, and M. Schattner
The immunoregulatory glycan-binding protein galectin-1 triggers human platelet activation
FASEB J,
April 1, 2008;
22(4):
1113 - 1123.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
I. Shalev, H. Liu, C. Koscik, A. Bartczak, M. Javadi, K. M. Wong, A. Maknojia, W. He, M. F. Liu, J. Diao, et al.
Targeted Deletion of fgl2 Leads to Impaired Regulatory T Cell Activity and Development of Autoimmune Glomerulonephritis
J. Immunol.,
January 1, 2008;
180(1):
249 - 260.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Kubach, P. Lutter, T. Bopp, S. Stoll, C. Becker, E. Huter, C. Richter, P. Weingarten, T. Warger, J. Knop, et al.
Human CD4+CD25+ regulatory T cells: proteome analysis identifies galectin-10 as a novel marker essential for their anergy and suppressive function
Blood,
September 1, 2007;
110(5):
1550 - 1558.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. K. Gandhi, G. Moll, C. Smith, U. Dua, E. Lambley, O. Ramuz, D. Gill, P. Marlton, J. F. Seymour, and R. Khanna
Galectin-1 mediated suppression of Epstein-Barr virus specific T-cell immunity in classic Hodgkin lymphoma
Blood,
August 15, 2007;
110(4):
1326 - 1329.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Juszczynski, J. Ouyang, S. Monti, S. J. Rodig, K. Takeyama, J. Abramson, W. Chen, J. L. Kutok, G. A. Rabinovich, and M. A. Shipp
The AP1-dependent secretion of galectin-1 by Reed Sternberg cells fosters immune privilege in classical Hodgkin lymphoma
PNAS,
August 7, 2007;
104(32):
13134 - 13139.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
